Bottom line
What is HDVAX's expense ratio?
HDVAX's expense ratio is 0.98%, or about $98 a year on every $10,000 invested. That is more expensive than 58% of international stock funds we track (median 0.9%). This share class also charges a front-end sales load of up to 5.5%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Feb 26, 2026
HDVAX fee table
| Net expense ratio | 0.98% |
|---|---|
| Gross expense ratio | 0.98% |
| Management fee | 0.46% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.27% |
| Max front-end sales load | 5.5% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Feb 26, 2026
What HDVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| HDVAX | $644 | $845 | $1,062 | $1,685 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 0.98% expense ratio costs roughly $54,400 in lost growth, versus about $50,300 for the median international stock fund (0.9%).